Adiponectin diminishes platelet aggregation and sCD40L release. Potential role in the metabolic syndrome

American Journal of Physiology - Endocrinology and Metabolism

Volumn 298, Issue 5, 2010, Pages

  Restituto, P ^a   Colina, I ^b   Varo, J J ^a   Varo, N ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b Department of Internal Medicine ^*  (Spain)

Author keywords

P selectin; Platelet activation; Platelets; Soluble CD40 ligand

Indexed keywords

ADENOSINE DIPHOSPHATE; ADIPONECTIN; ADIPONECTIN RECEPTOR; ADRENALIN; CD40 LIGAND; COLLAGEN; PADGEM PROTEIN;

ADULT; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HYPOTHESIS; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MODULATION; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA; WESTERN BLOTTING;

ADIPONECTIN; ADULT; BLOTTING, WESTERN; CD40 LIGAND; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; P-SELECTIN; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RECEPTORS, ADIPONECTIN; RECOMBINANT PROTEINS;

EID: 77950817472     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00728.2009     Document Type: Article

References (29)

1. Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS, Stefanadis C. The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol 54: 669-677, 2009.
2. Desideri G, De Simone M, Iughetti L, Rosato T, Iezzi ML, Marinucci MC, Cofini V, Croce G, Passacquale G, Necozione S, Ferri C. Early activation of vascular endothelial cells and platelets in obese children. J Clin Endocrinol Metab 90: 3145-3152, 2005.
3. Dibello JR, Baylin A, Viali S, Tuitele J, Bausserman L, McGarvey ST. Adiponectin and type 2 diabetes in Samoan adults. Am J Hum Biol 21: 389-391, 2008.
4. Ekmekçi H, Ekmekçi OB, Erdine S, Sönmez H, Ataev Y, Oztürk Z, Bütün II, Gürel C, Kucur M, Turfaner N, Ulutin T, Purisa S, Vural VA. Effects of serum homocysteine and adiponectin levels on platelet aggregation in untreated patients with essential hypertension. J Thromb Thrombolysis 28: 418-424, 2008.
5. Elbatarny HS, Netherton SJ, Ovens JD, Ferguson AV, Maurice DH. Adiponectin, ghrelin, and leptin differentially influence human platelet and human vascular endothelial cell functions: implication in obesity-associated cardiovascular diseases. Eur J Pharmacol 558: 7-13, 2007.
6. Fujimatsu D, Kotooka N, Inoue T, Nishiyama M, Node K. Association between high molecular weight adiponectin levels and metabolic parameters. J Atheroscler Thromb 16: 553-559, 2009.
7. Guo LL, Pan Y, Jin HM. Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. Nephrol Dial Transplant 24: 1876-1883, 2009.
8. Han SH, Sakuma I, Shin EK, Koh KK. Antiatherosclerotic and antiinsulin resistance effects of adiponectin: basic and clinical studies. Prog Cardiovasc Dis 52: 126-140, 2009.
9. Jesri A, Okonofua EC, Egan BM. Platelet and white blood cell counts are elevated in patients with the metabolic syndrome. J Clin Hypertens (Greenwich) 7: 705-713, 2005.
10. Kato H, Kashiwagi H, Shiraga M, Tadokoro S, Kamae T, Ujiie H, Honda S, Miyata S, Ijiri Y, Yamamoto J, Maeda N, Funahashi T, Kurata Y, Shimomura I, Tomiyama Y, Kanakura Y. Adiponectin acts as an endogenous antithrombotic factor. Arterioscler Thromb Vasc Biol 26: 224-230, 2006.
11. Kawano J, Arora R. The role of adiponectin in obesity, diabetes, and cardiovascular disease. J Cardiometab Syndr 4: 44-49, 2009.
12. Lee WL, Lee WJ, Chen YT, Liu TJ, Liang KW, Ting CT, Huey-Herng Sheu W. The presence of metabolic syndrome is independently associated with elevated serum CD40 ligand and disease severity in patients with symptomatic coronary artery disease. Metabolism 55: 1029-1034, 2006.
13. Lohsoonthorn V, Jiamjarasrungsi W, Williams MA. Association of hematological parameters with clustered components of metabolic syndrome among professional and office workers in Bangkok, Thailand. Diabetes Metab Syndr 1: 143-149, 2007.
14. Nam JS, Park JS, Cho MH, Jee SH, Lee HS, Ahn CW, Lowe WL Jr, Kim KR. The association between pulse wave velocity and metabolic syndrome and adiponectin in patients with impaired fasting glucose: cardiovascular risks and adiponectin in IFG. Diabetes Res Clin Pract 84: 145-151, 2009.
15. Natal C, Restituto P, Inigo C, Colina I, Diez J, Varo N. The proinflammatory mediator CD40 ligand is increased in the metabolic syndrome and modulated by adiponectin. J Clin Endocrinol Metab 93: 2319-2327, 2008.
16. Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, Engel J, Brownlee M, Scherer PE. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem 278: 9073-9085, 2003.
17. Pastor-Perez F, Marin F. Hypertension, aortic sclerosis and the prothrombotic state: understanding the complex interaction. J Hum Hypertens 23: 287-288, 2009.
18. Raffaelli F, Nanetti L, D'Angelo M, Montecchiani G, Alidori A, Montesi L, Faloia E, Vignini A, Mazzanti L. Interactions between lipoproteins and platelet membranes in obesity. Obesity (Silver Spring) 17: 1375-1380, 2009.
19. Riba R, Patel B, Aburima A, Naseem KM. Globular adiponectin increases cGMP formation in blood platelets independently of nitric oxide. J Thromb Haemost 6: 2121-2131, 2008.
20. Rosito GA, D'Agostino RB, Massaro J, Lipinska I, Mittleman MA, Sutherland P, Wilson PW, Levy D, Muller JE, Tofler GH. Association between obesity and a prothrombotic state: the Framingham Offspring Study. Thromb Haemost 91: 683-689, 2004.
21. Saely CH, Risch L, Hoefle G, Rein P, Muendlein A, Marte T, Aczel S, Langer P, Drexel H. Low serum adiponectin is independently associated with both the metabolic syndrome and angiographically determined coronary atherosclerosis. Clin Chim Acta 383: 97-102, 2007.
22. Salas-Salvado J, Granada M, Bullo M, Corominas A, Casas P, Foz M. Plasma adiponectin distribution in a Mediterranean population and its association with cardiovascular risk factors and metabolic syndrome. Metabolism 56: 1486-1492, 2007.
23. Schneider DJ, Hardison RM, Lopes N, Sobel BE, Brooks MM. Association between increased platelet P-selectin expression and obesity in patients with type 2 diabetes: a BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) substudy. Diabetes Care 32: 944-949, 2009.
24. Serebruany VL, Malinin A, Ong S, Atar D. Patients with metabolic syndrome exhibit higher platelet activity than those with conventional risk factors for vascular disease. J Thromb Thrombolysis 25: 207-213, 2008.
25. Vaduganathan M, Alviar CL, Arikan ME, Tellez A, Guthikonda S, DeLao T, Granada JF, Kleiman NS, Ballantyne CM, Lev EI. Platelet reactivity and response to aspirin in subjects with the metabolic syndrome. Am Heart J 156: e1001-1002, e1007, 2008.
26. Varo N, Libby P, Nuzzo R, Italiano J, Doria A, Schonbeck U. Elevated release of sCD40L from platelets of diabetic patients by thrombin, glucose and advanced glycation end products. Diab Vasc Dis Res 2: 81-87, 2005.
27. Varo N, Vicent D, Libby P, Nuzzo R, Calle-Pascual AL, Bernal MR, Fernandez-Cruz A, Veves A, Jarolim P, Varo JJ, Goldfine A, Horton E, Schonbeck U. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. Circulation 107: 2664-2669, 2003.
28. Wang YY, Lin SY, Liu PH, Cheung BM, Lai WA. Association between hematological parameters and metabolic syndrome components in a Chinese population. J Diabetes Complications 18: 322-327, 2004.
29. Winther K, Gleerup G, Hedner T. Enhanced risk of thromboembolic disease in hypertension from platelet hyperfunction and decreased fibrinolytic activity: has antihypertensive therapy any influence? J Cardiovasc Pharmacol 19, Suppl 3: S21-S24, 1992.